Therapy for Latent HIV-1 Infection: The Role of Histone Deacetylase Inhibitors. Issue 4 (August 2014)

• Record Type: Journal Article
• Authors: McManamy, Mary E Manson; Hakre, Shweta; Verdin, Eric M; Margolis, David M
• Is Part Of: Antiviral chemistry & chemotherapy. Volume 23:Issue 4(2014)
• Page Start: 145
• Page End: 149
• Publication Date: 2014-08
• Subjects: Antiviral agents -- Periodicals; Chemotherapy -- Periodicals; 615.7924
• DOI: 10.3851/IMP2551
• Languages: English
• ISSNs: 0956-3202

Abstract

Persistence of HIV-1 in latently infected CD4 + T-cells prevents eradication in HIV-infected treated patients. Latency is characterized by a reversible silencing of transcription of integrated HIV-1. Several molecular mechanisms have been described which contribute to latency, including the establishment and maintenance of repressive chromatin on the HIV-1 promoter. Histone deacetylation is a landmark modification associated with transcriptional repression of the HIV-1 promoter and inhibition of histone deacetylase enzymes (HDACs) reactivates latent HIV-1. Here, we review the different HDAC inhibitors that have been studied in HIV-1 latency and their therapeutic potential in reactivating latent HIV-1.